# International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia

> **NCT02724163** · PHASE3 · RECRUITING · sponsor: **University of Birmingham** · enrollment: 700 (estimated)

## Conditions studied

- Acute Myeloid Leukaemia

## Interventions

- **DRUG:** Gemtuzumab ozogamicin
- **DRUG:** Liposomal daunorubicin
- **DRUG:** Mitoxantrone
- **DRUG:** Fludarabine
- **DRUG:** Cytarabine
- **DRUG:** Busulfan
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT02724163
- **Lead sponsor:** University of Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2016-04
- **Primary completion:** 2031-12
- **Final completion:** 2032-12
- **Target enrollment:** 700 (ESTIMATED)
- **Last updated:** 2021-10-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02724163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02724163, "International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02724163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*